Association of PHD3 and HIF2α gene expression with clinicopathological characteristics in human hepatocellular carcinoma

Jiang,Liang; Liu,Qiu‑Long; Liang,Qi‑Lian; Zhang,Hui‑Jie; Ou,Wen‑Ting; Yuan,Gao‑Le

doi:10.3892/ol.2017.7302

Association of PHD3 and HIF2α gene expression with clinicopathological characteristics in human hepatocellular carcinoma

Authors:
- Liang Jiang
- Qiu‑Long Liu
- Qi‑Lian Liang
- Hui‑Jie Zhang
- Wen‑Ting Ou
- Gao‑Le Yuan
View Affiliations

Affiliations: Oncology Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China
Published online on: October 31, 2017 https://doi.org/10.3892/ol.2017.7302
Pages: 545-551

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Egl-9 family hypoxia-inducible factor (HIF)3/prolyl hydroxylase 3 (EGLN3/PHD3) serves a role in the progression and prognosis of cancer. PHD3 is able to induce apoptosis in HepG2 cells. In the present study, the protein levels of PHD3 and HIF2α were analyzed by western blot analysis and immunohistochemistry in 84 paired hepatocellular carcinoma (HCC) tissues and adjacent non‑tumor liver tissues. The mRNA levels of PHD3 and HIF2α were analyzed by reverse transcription-quantitative polymerase chain reaction. PHD3 was overexpressed in HCC tissues compared with adjacent liver tissues (mRNA expression: P<0.001; protein expression: P=0.003; immunohistochemistry positive rate: P=0.001). The high level of expression of PHD3 in HCC tissues was associated with good differentiation (mRNA expression: P=0.002; protein expression: P<0.001) and small tumor size (mRNA expression: P<0.001; protein expression: P=0.002). In addition, HIF2α expression was lower in HCC tissues compared with adjacent liver tissues (mRNA expression: P<0.001; protein expression: P=0.002; immunohistochemistry positive rate: P=0.002). No statistically significant associations were identified between HIF2α expression and clinicopathological characteristics. Pearson's and Spearman's correlation coefficients revealed no correlation between HIF2α and PHD3 expression in HCC. In conclusion, PHD3 expression acts as a favorable prognostic marker for patients with HCC. There is no correlation between PHD3 and HIF2α expression in HCC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 142:1264–1273, e1. 2012. View Article : Google Scholar : PubMed/NCBI
3	Blechacz B and Mishra L: Hepatocellular carcinoma biology. Recent Results Cancer Res. 190:1–20. 2013. View Article : Google Scholar : PubMed/NCBI
4	Webb JD, Coleman ML and Pugh CW: Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. Cell Mol Life Sci. 66:3539–3554. 2009. View Article : Google Scholar : PubMed/NCBI
5	Stegeman H, Span PN, Kaanders JH and Bussink J: Improving chemoradiation efficacy by PI3-K/AKT inhibition. Cancer Treat Rev. 40:1182–1191. 2014. View Article : Google Scholar : PubMed/NCBI
6	Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
7	Semenza GL: Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 29:625–634. 2010. View Article : Google Scholar : PubMed/NCBI
8	Bangoura G, Liu ZS, Qian Q, Jiang CQ, Yang GF and Jing S: Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma. World J Gastroenterol. 13:3176–3182. 2007. View Article : Google Scholar : PubMed/NCBI
9	Tong WW, Tong GH, Chen XX, Zheng HC and Wang YZ: HIF2α is associated with poor prognosis and affects the expression levels of survivin and cyclin D1 in gastric carcinoma. Int J Oncol. 46:233–242. 2015. View Article : Google Scholar : PubMed/NCBI
10	Putra AC, Eguchi H, Lee KL, Yamane Y, Gustine E, Isobe T, Nishiyama M, Hiyama K, Poellinger L and Tanimoto K: The A Allele at rs13419896 of EPAS1 is associated with enhanced expression and poor prognosis for non-small cell lung cancer. PLoS One. 10:e01344962015. View Article : Google Scholar : PubMed/NCBI
11	Sun HX, Xu Y, Yang XR, Wang WM, Bai H, Shi RY, Nayar SK, Devbhandari RP, He YZ, Zhu QF, et al: Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/E2F transcription factor 1-dependent apoptotic pathway. Hepatology. 57:1088–1097. 2013. View Article : Google Scholar : PubMed/NCBI
12	Yang SL, Liu LP, Jiang JX, Xiong ZF, He QJ and Wu C: The correlation of expression levels of HIF-1α and HIF-2α in hepatocellular carcinoma with capsular invasion, portal vein tumor thrombi and patients' clinical outcome. Jpn J Clin Oncol. 44:159–167. 2014. View Article : Google Scholar : PubMed/NCBI
13	Bruick RK and McKnight SL: A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 294:1337–1340. 2001. View Article : Google Scholar : PubMed/NCBI
14	Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ and Gleadle JM: Differential function of the prolyl hydroxylases PHD1, PHD2 and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem. 279:38458–38465. 2004. View Article : Google Scholar : PubMed/NCBI
15	Peurala E, Koivunen P, Bloigu R, Huaapasaari KM and Jukkola-Cuorinen A: Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients. Breast Cancer Res Treat. 133:179–188. 2012. View Article : Google Scholar : PubMed/NCBI
16	Michiels C, Tellier C and Feron O: Cycling hypoxia: A key feature of the tumor microenvironment. Biochim Biophys Acta. 1866:76–86. 2016.PubMed/NCBI
17	Tanaka T, Torigoe T, Hirohashi Y, Sato E, Honma I, Kitamura H, Masumori N, Tsukamoto T and Sato N: Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma. J Cancer Res Clin Oncol. 140:503–513. 2014. View Article : Google Scholar : PubMed/NCBI
18	Su C, Huang K, Sun L, Yang D, Zheng H, Gao C, Tong J and Zhang Q: Overexpression of the HIF hydroxylase PHD3 is a favorable prognosticator for gastric cancer. Med Oncol. 29:2710–2715. 2012. View Article : Google Scholar : PubMed/NCBI
19	Chen S, Zhang J, Li X, Luo X, Fang J and Chen H: The expression of prolyl hydroxylase domain enzymes are up-regulated and negatively correlated with Bcl-2 in non-small cell lung cancer. Mol Cell Biochem. 358:257–263. 2011. View Article : Google Scholar : PubMed/NCBI
20	Andersen S, Donnem T, Stenvold H, Al-Saad S, Al-Shibli K, Busund LT and Bremnes RM: Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival. PLoS One. 6:e238472011. View Article : Google Scholar : PubMed/NCBI
21	Gossage L, Zaitoun A, Fareed KR, Turley H, Aloysius M, Lobo DN, Harris AL and Madhusudan S: Expression of key hypoxia sensing prolyl-hydroxylases PHD1, −2 and −3 in pancreaticobiliary cancer. Histopathology. 56:908–920. 2010. View Article : Google Scholar : PubMed/NCBI
22	Cui L, Qu J, Dang S, Mao Z, Wang X, Fan X, Sun K and Zhang J: Prolyl hydroxylase 3 inhibited the tumorigenecity of gastric cancer cells. Mol Carcinog. 53:736–743. 2014. View Article : Google Scholar : PubMed/NCBI
23	Liu QL, Liang QL, Li ZY, Zhou Y, Ou WT and Huang ZG: Function and expression of prolyl hydroxylase 3 in cancers. Arch Med Sci. 9:589–593. 2013. View Article : Google Scholar : PubMed/NCBI
24	Xue J, Li X, Jiao S, Wei Y, Wu G and Fang J: Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. Gastroenterology. 138:606–615. 2010. View Article : Google Scholar : PubMed/NCBI
25	Zhou Y, Liang QL, Ou WT, Liu QL, Zhang XN, Li ZY and Huang X: Effect of stable transfection with PHD3 on growth and proliferation of HepG2 cells in vitro and in vivo. Int J Clin Exp Med. 7:2197–2203. 2014.PubMed/NCBI
26	Henze AT, Garvalov BK, Seidel S, Cuesta AM, Ritter M, Filatova A, Foss F, Dopeso H, Essmann CL, Maxwell PH, et al: Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR. Nat Commun. 5:55822014. View Article : Google Scholar : PubMed/NCBI
27	Garvalov BK, Foss F, Henze AT, Bethani I, Gräf-Höchst S, Singh D, Filatova A, Dopeso H, Seidel S, Damm M, et al: PHD3 regulates EGFR internalization and signalling in tumours. Nat Commun. 5:55772014. View Article : Google Scholar : PubMed/NCBI
28	Liang QL, Li ZY, Zhou Y, Liu QL, Ou WT and Huang ZG: Construction of a recombinant eukaryotic expression vector containing PHD3 gene and its expression in HepG2 cells. J Exp Clin Cancer Res. 31:642012. View Article : Google Scholar : PubMed/NCBI
29	Su Y, Loos M, Giese N, Hines OJ, Diebold I, Görlach A, Metzen E, Pastorekova S, Friess H and Büchler P: PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer. Br J Cancer. 103:1571–1579. 2010. View Article : Google Scholar : PubMed/NCBI
30	International Union Against Cancer (UICC), . Sobin LH and Wittekind C: TNM classification of malign ant tumors. 6th. New York: Wiley-Liss; pp. 81–83. 2002
31	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI